Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Claritin patent litigation

This article was originally published in The Tan Sheet

Executive Summary

Consolidated pretrial proceedings in Newark, N.J. federal court indefinitely delayed due to Judge Joseph Greenaway's decision to recuse himself. Greenaway formerly worked for J&J's law department, and any judicial ruling on the validity, enforceability of Schering-Plough's patents for loratadine, desloratadine could affect S-P's infringement lawsuit against J&J division McNeil, which is seeking FDA approval to market OTC loratadine (1"The Tan Sheet" Feb. 4, 2002, p. 3). Separately, Zenith Goldline, now known as Ivax Pharmaceuticals, has agreed to withdraw its ANDA for loratadine 10 mg tablets, according to an April 18 stipulated order. Schering remains a plaintiff in more than a half dozen patent lawsuits in an attempt to fend off generic competition to its Claritin franchise...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel